In this study, we aimed to assess the clinical significance of PDIA3 in endometrial cancer by evaluating its expression in public datasets and primary tumor samples from participating hospitals, with the goal of identifying its potential as a novel biomarker. The gene discussed is PDIA3; the disease is endometrial cancer.